☰

Nathan Elliott Fishkin - Publications

Affiliations: 
2004 Columbia University, New York, NY 
Tree Info Similar researchers PubMed Report error

35 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Reid EE, Archer KE, Shizuka M, Wilhelm A, Yoder NC, Bai C, Fishkin NE, Harris L, Maloney EK, Salomon P, Hong E, Wu R, Ab O, Jin S, Lai KC, et al. Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody-Drug Conjugates (ADCs). Acs Medicinal Chemistry Letters. 10: 1193-1197. PMID 31413805 DOI: 10.1021/Acsmedchemlett.9B00240  0.312
2016 Miller ML, Fishkin NE, Li W, Whiteman KR, Kovtun Y, Reid EE, Archer KE, Maloney EK, Audette CA, Mayo MF, Wilhelm A, Modafferi HA, Singh R, Pinkas J, Goldmacher V, et al. A New Class of Antibody-Drug Conjugates with Potent DNA Alkylating Activity. Molecular Cancer Therapeutics. PMID 27216304 DOI: 10.1158/1535-7163.Mct-16-0184  0.31
2016 Singh R, Setiady YY, Ponte J, Kovtun YV, Lai KC, Hong EE, Fishkin N, Dong L, Jones GE, Coccia JA, Lanieri L, Veale K, Costoplus JA, Skaletskaya A, Gabriel R, et al. A new, triglycyl peptide linker for antibody-drug conjugates (ADCs) with improved targeted killing of cancer cells. Molecular Cancer Therapeutics. PMID 27197308 DOI: 10.1158/1535-7163.Mct-16-0021  0.351
2016 Ponte JF, Sun X, Yoder NC, Fishkin N, Laleau R, Coccia J, Lanieri L, Bogalhas M, Wang L, Wilhelm SD, Widdison WC, Keating TA, Chari RV, Erickson H, Lambert JM. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-linked Antibody-Maytansinoid Conjugates. Bioconjugate Chemistry. PMID 27174129 DOI: 10.1021/Acs.Bioconjchem.6B00117  0.317
2016 Harris L, Lanieri L, Ponte J, Maloney E, Bartle L, Ab O, Costoplus J, Rui L, Pinkas J, Chari R, Keating T, Tavares D, Fishkin N. Abstract 2967:In vitroandin vivoactivity of site-specific antibody-drug conjugates (ADCs) with 2 and 4 maytansinoid molecules per antibody prepared through conjugation to SeriMabs (N-terminal serine engineered Abs) Cancer Research. 76: 2967-2967. DOI: 10.1158/1538-7445.Am2016-2967  0.376
2016 Vitharana D, Wilhelm A, Harris L, Archer K, Shizuka M, Maloney E, Ab O, Laleau R, Sun X, Pinkas J, Miller M, Chari R, Keating T, Fishkin N. Abstract 2965:In vitroandin vivoactivity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent Cancer Research. 76: 2965-2965. DOI: 10.1158/1538-7445.Am2016-2965  0.359
2015 Widdison WC, Ponte JF, Coccia JA, Lanieri L, Setiady Y, Dong L, Skaletskaya A, Hong EE, Wu R, Qiu Q, Singh R, Salomon P, Fishkin N, Harris L, Maloney EK, et al. Development of anilino-maytansinoid ADCs that efficiently release cytotoxic metabolites in cancer cells and induce high levels of bystander killing. Bioconjugate Chemistry. PMID 26355774 DOI: 10.1021/Acs.Bioconjchem.5B00430  0.325
2015 Tavares D, Rui L, Ab O, Harris L, Maloney E, Keating T, Chittenden T, Fishkin N. Abstract 653: Antibody-drug conjugates: engineered N-terminal serine residues as a novel approach for site-specific conjugation Cancer Research. 75: 653-653. DOI: 10.1158/1538-7445.Am2015-653  0.321
2015 Miller ML, Shizuka M, Fishkin N, Reid E, Archer K, Maloney E, Bai C, Ab O, Yoder NC, Wu R, Hong E, Bogalhas M, Wilhelm A, Whiteman K, Chari R. Abstract 652: Antibody-drug conjugates (ADCs) of indolino-benzodiazepine DNA-alkylating agents Cancer Research. 75: 652-652. DOI: 10.1158/1538-7445.Am2015-652  0.343
2015 Harris L, Tavares D, Rui L, Maloney E, Wilhelm A, Costoplus J, Archer K, Bogalhas M, Harvey L, Wu R, Chen X, Xu X, Connaughton S, Wang L, Whiteman K, ... ... Fishkin N, et al. Abstract 647: SeriMabs: N-terminal serine modification enables modular, site-specific payload incorporation into antibody-drug conjugates (ADCs) Cancer Research. 75: 647-647. DOI: 10.1158/1538-7445.Am2015-647  0.35
2014 Whiteman K, Audette C, Dandeneau A, Ellis M, Fishkin N, Harvey L, Johnson H, Kovtun Y, Maloney E, Miller M, Wilhelm A, Chari R. Abstract 2644: Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models Cancer Research. 74: 2644-2644. DOI: 10.1158/1538-7445.Am2014-2644  0.334
2014 Widdison WC, Ponte J, Coccia J, Setiady Y, Dong L, Skaletskaya A, Fishkin N, Kovtun Y, Wu R, Singh R, Harris L, Jones G, Lanieri L, Maloney E, Audette C, et al. Abstract 1618: New peptide-linked anilino-maytansinoid antibody-drug conjugates (ADCs) for the treatment of cancer Cancer Research. 74: 1618-1618. DOI: 10.1158/1538-7445.Am2014-1618  0.329
2013 Ponte JF, Sun X, Yoder NC, Fishkin N, Wilhelm S, Hawes SJ, Widdison W, Mastico RA, Pinkas J, Chari RJ, Lutz RJ, Erickson HK. Abstract 5677: The anti-EGFR ADC, IMGN289 displays favorable pharmacokinetic properties. Cancer Research. 73: 5677-5677. DOI: 10.1158/1538-7445.Am2013-5677  0.317
2013 Singh R, Fishkin N, Kovtun Y, Jones G, Ponte J, Erickson H, Hong E, Setiady Y, Dandeneau A, Lai K, Coccia J, Lanieri L, Bouchard J, Veale K, Chari R, et al. Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C164  0.379
2013 Whiteman K, Johnson H, Wilhelm A, Miller M, Li W, Reid E, Archer K, Fishkin N, Dandeneau A, Maloney E, Pinkas J, Chari R. Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C162  0.329
2013 Miller M, Fishkin N, Li W, Reid E, Archer K, Maloney E, Kovtun Y, Jones G, Ellis M, Singh R, Whiteman K, Pinkas J, Chari R. Abstract C160: New class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C160  0.351
2011 Wu Y, Zhou J, Fishkin N, Rittmann BE, Sparrow JR. Enzymatic degradation of A2E, a retinal pigment epithelial lipofuscin bisretinoid. Journal of the American Chemical Society. 133: 849-57. PMID 21166406 DOI: 10.1021/Ja107195U  0.45
2009 Wu Y, Fishkin NE, Pande A, Pande J, Sparrow JR. Novel lipofuscin bisretinoids prominent in human retina and in a model of recessive Stargardt disease. The Journal of Biological Chemistry. 284: 20155-66. PMID 19478335 DOI: 10.1074/Jbc.M109.021345  0.494
2009 Miller M, Fishkin N, Li W, Leece B, Mayo M, Jones G, Reid E, Archer K, Maloney E, Kovtun Y, Pinkas J, Singh R, Chari R. Abstract B126: Potent antigen‐specific anti‐tumor activity observed with antibody‐drug conjugates (ADCs) made using a new class of DNA‐crosslinking agents Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B126  0.333
2009 Maloney E, Fishkin N, Chari R, Singh R. Abstract B120: Designing potent antibody‐drug conjugates: The impact of lysosomal processing efficiency and conjugate linker selection on anticancer activity Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-B120  0.441
2008 Chen Y, Herrmann R, Fishkin N, Henklein P, Nakanishi K, Ernst OP. Synthesis and spectroscopic characterization of photo-affinity peptide ligands to study rhodopsin-G protein interaction. Photochemistry and Photobiology. 84: 831-8. PMID 18282180 DOI: 10.1111/J.1751-1097.2008.00304.X  0.414
2007 Kim SR, Jang YP, Jockusch S, Fishkin NE, Turro NJ, Sparrow JR. The all-trans-retinal dimer series of lipofuscin pigments in retinal pigment epithelial cells in a recessive Stargardt disease model. Proceedings of the National Academy of Sciences of the United States of America. 104: 19273-8. PMID 18048333 DOI: 10.1073/Pnas.0708714104  0.449
2005 Rogge B, Itagaki Y, Fishkin N, Levi E, Rühl R, Yi SS, Nakanishi K, Hammerling U. Retinoylserine and retinoylalanine, natural products of the moth Trichoplusia ni. Journal of Natural Products. 68: 1536-40. PMID 16252921 DOI: 10.1021/Np0496791  0.549
2005 Furuta T, Sakai M, Hayashi H, Asakawa T, Kataoka F, Fujii S, Suzuki T, Suzuki Y, Tanaka K, Fishkin N, Nakanishi K. Design and synthesis of artificial phospholipid for selective cleavage of integral membrane protein. Chemical Communications (Cambridge, England). 4575-7. PMID 16158119 DOI: 10.1039/B507917A  0.383
2005 Fishkin NE, Sparrow JR, Allikmets R, Nakanishi K. Isolation and characterization of a retinal pigment epithelial cell fluorophore: an all-trans-retinal dimer conjugate. Proceedings of the National Academy of Sciences of the United States of America. 102: 7091-6. PMID 15870200 DOI: 10.1073/Pnas.0501266102  0.541
2004 Fishkin N, Pescitelli G, Sparrow JR, Nakanishi K, Berova N. Absolute configurational determination of an all-trans-retinal dimer isolated from photoreceptor outer segments. Chirality. 16: 637-41. PMID 15382205 DOI: 10.1002/Chir.20084  0.465
2004 Kim SR, Fishkin N, Kong J, Nakanishi K, Allikmets R, Sparrow JR. Rpe65 Leu450Met variant is associated with reduced levels of the retinal pigment epithelium lipofuscin fluorophores A2E and iso-A2E. Proceedings of the National Academy of Sciences of the United States of America. 101: 11668-72. PMID 15277666 DOI: 10.1073/Pnas.0403499101  0.584
2004 Fishkin N, Berova N, Nakanishi K. Primary events in dim light vision: a chemical and spectroscopic approach toward understanding protein/chromophore interactions in rhodopsin. Chemical Record (New York, N.Y.). 4: 120-35. PMID 15073879 DOI: 10.1002/Tcr.20000  0.512
2003 Sparrow JR, Fishkin N, Zhou J, Cai B, Jang YP, Krane S, Itagaki Y, Nakanishi K. A2E, a byproduct of the visual cycle. Vision Research. 43: 2983-90. PMID 14611934 DOI: 10.1016/S0042-6989(03)00475-9  0.684
2003 Ivic L, Sands TT, Fishkin N, Nakanishi K, Kriegstein AR, Strømgaard K. Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABA(A) receptors. The Journal of Biological Chemistry. 278: 49279-85. PMID 14504293 DOI: 10.1074/Jbc.M304034200  0.376
2003 Fishkin N, Jang YP, Itagaki Y, Sparrow JR, Nakanishi K. A2-rhodopsin: a new fluorophore isolated from photoreceptor outer segments. Organic & Biomolecular Chemistry. 1: 1101-5. PMID 12926382 DOI: 10.1039/B212213H  0.639
2002 Fujimoto Y, Fishkin N, Pescitelli G, Decatur J, Berova N, Nakanishi K. Solution and biologically relevant conformations of enantiomeric 11-cis-locked cyclopropyl retinals Journal of the American Chemical Society. 124: 7294-7302. PMID 12071738 DOI: 10.1021/Ja020083E  0.542
2002 Ben-Shabat S, Parish CA, Vollmer HR, Itagaki Y, Fishkin N, Nakanishi K, Sparrow JR. Biosynthetic studies of A2E, a major fluorophore of retinal pigment epithelial lipofuscin. The Journal of Biological Chemistry. 277: 7183-90. PMID 11756445 DOI: 10.1074/Jbc.M108981200  0.654
2002 Nakanishi K, Berova N, Fishkin N, Fujioka N. Bioorganic Studies on Rhodopsins Journal of the Chinese Chemical Society. 49: 443-451. DOI: 10.1002/Jccs.200200070  0.407
2001 Fujimoto Y, Ishihara J, Maki S, Fujioka N, Wang T, Furuta T, Fishkin N, Borhan B, Berova N, Nakanishi K. On the bioactive conformation of the rhodopsin chromophore: absolute sense of twist around the 6-s-cis bond. Chemistry (Weinheim An Der Bergstrasse, Germany). 7: 4198-204. PMID 11686599 DOI: 10.1002/1521-3765(20011001)7:19<4198::Aid-Chem4198>3.0.Co;2-X  0.661
Show low-probability matches.